Clinic
Prospect Manchester Hospital, INC.
Prospect Manchester Hospital, INC. was paid $69.20M by Medicaid between Jan 2018 and Dec 2024, across 410 billing codes. Its largest line is G0384, Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) — 15% of everything it billed.
33Billing provider infoPROSPECT MANCHESTER HOSPITAL, INC.
MANCHESTER, CT 06040
MANCHESTER, CT 06040
33aNPI1316394638assigned 05/17/2016
33bProvider typeEmergency Care Clinic/Center
28Total paid$69.20M
24GClaims2,197,712
24DCodes billed410
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#5 of 6
Median peer was paid$80.66M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 362,426 | $11.01M | |
| 2019 | 340,396 | $11.66M | |
| 2020 | 285,286 | $8.80M | |
| 2021 | 319,045 | $9.70M | |
| 2022 | 311,067 | $9.74M | |
| 2023 | 285,830 | $9.63M | |
| 2024incomplete | 293,662 | $8.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 15% | 17,694 | 15,740 | $10.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 19,599 | 16,960 | $6.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.8% | 17,616 | 15,448 | $4.02M |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 5.4% | 16,689 | 15,504 | $3.75M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 23,540 | 20,245 | $3.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.7% | 18,924 | 16,808 | $3.23M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 4.1% | 16,818 | 15,603 | $2.84M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.0% | 2,952 | 2,815 | $2.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 8,427 | 7,801 | $1.93M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 4,427 | 4,196 | $1.89M |
| G0379 | Direct admission of patient for hospital observation care | 2.1% | 2,766 | 2,207 | $1.44M |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.0% | 10,546 | 1,784 | $1.36M |
398 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 34,757 | $1.24M |
| 90834 | Psychotherapy session, about 45 minutes | 1.4% | 23,539 | $991K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 16,240 | $977K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.4% | 1,246 | $957K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 9,295 | $933K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,348 | $816K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 1,638 | $776K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 16,941 | $756K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 4,833 | $754K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 13,902 | $741K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 13,657 | $699K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 18,998 | $692K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,578 | $672K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 824 | $661K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 2,941 | $574K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,483 | $510K |
| 97597 | <1% | 6,382 | $504K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,788 | $474K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,878 | $471K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,891 | $429K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,332 | $421K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,816 | $413K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,040 | $413K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 2,962 | $386K |
| 97010 | <1% | 20,537 | $367K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,783 | $306K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29,213 | $287K |
| 80053 | Comprehensive metabolic panel | <1% | 41,213 | $271K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 103,510 | $266K |
| 97161 | <1% | 4,578 | $254K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,808 | $253K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 8,839 | $242K |
| 80061 | Lipid panel | <1% | 26,805 | $238K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,251 | $228K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,861 | $213K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,205 | $211K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,768 | $206K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,170 | $206K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,996 | $199K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,995 | $199K |
| 59025 | Fetal non-stress test | <1% | 1,790 | $193K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,205 | $185K |
| 97035 | <1% | 10,248 | $184K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 12,037 | $171K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 39 | $170K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,424 | $162K |
| 93971 | <1% | 2,206 | $149K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 161,638 | $142K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 10,529 | $139K |
| 86900 | <1% | 5,978 | $136K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,662 | $129K |
| 76830 | Ultrasound, transvaginal | <1% | 1,444 | $129K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,699 | $128K |
| 93798 | <1% | 1,968 | $127K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,311 | $124K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,100 | $118K |
| 76801 | <1% | 1,127 | $114K | |
| 82947 | <1% | 45,946 | $112K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 188 | $110K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,288 | $108K |
| 71250 | <1% | 2,070 | $107K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,850 | $104K |
| 97162 | <1% | 2,229 | $103K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 349 | $96K |
| 97012 | <1% | 1,861 | $95K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,316 | $94K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,899 | $93K |
| 82728 | <1% | 9,732 | $86K | |
| 97014 | <1% | 3,280 | $83K | |
| 97113 | <1% | 1,931 | $82K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,428 | $70K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,866 | $68K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,296 | $65K |
| 93970 | <1% | 499 | $61K | |
| 82607 | <1% | 6,405 | $60K | |
| 95811 | <1% | 94 | $56K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 534 | $56K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,372 | $51K |
| 83550 | <1% | 8,101 | $47K | |
| 86780 | <1% | 4,238 | $46K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,919 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,509 | $40K |
| 84153 | <1% | 3,363 | $40K | |
| 83540 | <1% | 8,962 | $39K | |
| 86803 | <1% | 3,806 | $38K | |
| 82746 | <1% | 4,004 | $37K | |
| 84439 | <1% | 6,338 | $36K | |
| 86885 | <1% | 3,108 | $35K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 73 | $33K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,087 | $31K |
| 73630 | <1% | 3,051 | $30K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,614 | $30K |
| 97165 | <1% | 448 | $30K | |
| 83615 | <1% | 8,781 | $29K | |
| 93017 | <1% | 1,869 | $28K | |
| 43450 | <1% | 110 | $27K | |
| 86617 | <1% | 1,348 | $27K | |
| 70486 | <1% | 800 | $27K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,257 | $26K |
| 83735 | <1% | 18,283 | $25K | |
| 72100 | <1% | 2,139 | $25K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 99 | $24K |
| 73564 | <1% | 2,144 | $24K | |
| 82784 | <1% | 2,002 | $24K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,204 | $23K |
| G0378 | Hospital observation service, per hour | <1% | 9,785 | $23K |
| 85027 | <1% | 9,418 | $23K | |
| 87070 | <1% | 7,353 | $21K | |
| 72110 | <1% | 366 | $21K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 244 | $21K |
| 10060 | <1% | 133 | $21K | |
| 82570 | <1% | 8,377 | $20K | |
| 73030 | <1% | 2,708 | $20K | |
| 70496 | <1% | 124 | $19K | |
| 85610 | <1% | 16,448 | $19K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 174 | $19K |
| 87340 | <1% | 3,369 | $18K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,588 | $18K |
| 76642 | <1% | 317 | $18K | |
| 98968 | <1% | 372 | $17K | |
| 82043 | <1% | 4,885 | $17K | |
| 62323 | <1% | 65 | $17K | |
| 87186 | <1% | 5,933 | $16K | |
| 11043 | <1% | 57 | $16K | |
| 84403 | <1% | 789 | $16K | |
| 83970 | <1% | 887 | $16K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 105 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 271 | $15K |
| 80076 | <1% | 3,367 | $15K | |
| 86038 | <1% | 1,635 | $14K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 181 | $14K |
| 98967 | <1% | 326 | $13K | |
| 76536 | <1% | 186 | $13K | |
| 87493 | <1% | 706 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 626 | $12K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 45 | $12K |
| 94060 | <1% | 59 | $12K | |
| 74018 | <1% | 602 | $11K | |
| 73610 | <1% | 2,287 | $11K | |
| 84702 | <1% | 3,595 | $11K | |
| 83883 | <1% | 744 | $11K | |
| 86140 | <1% | 4,380 | $10K | |
| 73130 | <1% | 1,880 | $10K | |
| 86666 | <1% | 642 | $10K | |
| 85007 | <1% | 7,466 | $10K | |
| 86704 | <1% | 1,036 | $10K | |
| 76775 | <1% | 242 | $10K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 2,178 | $9K |
| 81001 | <1% | 19,373 | $9K | |
| 83690 | <1% | 22,286 | $9K | |
| 73502 | <1% | 1,271 | $9K | |
| 87625 | <1% | 903 | $8K | |
| 86403 | <1% | 2,371 | $8K | |
| 73562 | <1% | 1,340 | $8K | |
| 86334 | <1% | 720 | $8K | |
| 83880 | <1% | 5,713 | $8K | |
| 87077 | <1% | 3,170 | $8K | |
| 73110 | <1% | 1,275 | $8K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 6,904 | $8K |
| 85652 | <1% | 5,570 | $8K | |
| 84146 | <1% | 685 | $7K | |
| 97116 | <1% | 358 | $7K | |
| 87660 | <1% | 619 | $7K | |
| 87480 | <1% | 619 | $7K | |
| 87510 | <1% | 619 | $7K | |
| 82652 | <1% | 244 | $7K | |
| 84165 | <1% | 1,169 | $7K | |
| 83516 | <1% | 422 | $6K | |
| 86618 | <1% | 1,057 | $6K | |
| 86753 | <1% | 542 | $6K | |
| 86480 | <1% | 142 | $6K | |
| 84402 | <1% | 299 | $6K | |
| 80051 | <1% | 46,388 | $6K | |
| 87205 | <1% | 3,833 | $6K | |
| 82565 | <1% | 48,010 | $5K | |
| 80069 | <1% | 1,294 | $5K | |
| 86696 | <1% | 328 | $5K | |
| 86787 | <1% | 1,313 | $5K | |
| 86762 | <1% | 1,509 | $5K | |
| 71271 | <1% | 44 | $5K | |
| 88342 | <1% | 5,655 | $5K | |
| 84100 | <1% | 3,685 | $5K | |
| 80164 | <1% | 783 | $5K | |
| 82378 | <1% | 426 | $5K | |
| 85730 | <1% | 4,232 | $5K | |
| 88142 | <1% | 354 | $5K | |
| 82150 | <1% | 887 | $4K | |
| 90837 | Psychotherapy session, about an hour | <1% | 51 | $4K |
| 82105 | <1% | 335 | $4K | |
| 82247 | <1% | 38,030 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 149 | $4K |
| 72072 | <1% | 182 | $4K | |
| 82950 | <1% | 1,000 | $4K | |
| 86431 | <1% | 994 | $4K | |
| 70491 | <1% | 26 | $4K | |
| 83013 | <1% | 77 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,113 | $4K |
| 84450 | <1% | 39,283 | $4K | |
| 87427 | <1% | 586 | $4K | |
| 86695 | <1% | 328 | $4K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 49 | $3K |
| 84550 | <1% | 2,451 | $3K | |
| 84160 | <1% | 1,168 | $3K | |
| 83655 | <1% | 303 | $3K | |
| 87081 | <1% | 691 | $3K | |
| 82550 | <1% | 2,168 | $3K | |
| J3490 | Unclassified drugs | <1% | 100,885 | $3K |
| 83001 | <1% | 204 | $3K | |
| 87045 | <1% | 586 | $3K | |
| 87046 | <1% | 586 | $3K | |
| 82248 | <1% | 2,024 | $3K | |
| 85045 | <1% | 1,246 | $2K | |
| 86376 | <1% | 257 | $2K | |
| 84703 | <1% | 1,303 | $2K | |
| 84630 | <1% | 230 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $2K |
| 73700 | <1% | 45 | $2K | |
| 87177 | <1% | 360 | $2K | |
| 82977 | <1% | 501 | $2K | |
| 85379 | <1% | 4,513 | $2K | |
| 73140 | <1% | 392 | $2K | |
| 83721 | <1% | 333 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $2K |
| 82310 | <1% | 7,341 | $2K | |
| 82172 | <1% | 242 | $2K | |
| 84156 | <1% | 1,289 | $2K | |
| 82140 | <1% | 602 | $2K | |
| 70498 | <1% | 131 | $2K | |
| 72131 | <1% | 62 | $2K | |
| 84484 | <1% | 16,149 | $2K | |
| 73080 | <1% | 382 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,537 | $1K |
| 87040 | <1% | 2,846 | $1K | |
| 81003 | <1% | 986 | $1K | |
| 29515 | <1% | 16 | $1K | |
| 86328 | <1% | 52 | $1K | |
| 91065 | <1% | 12 | $1K | |
| 84520 | <1% | 47,207 | $1K | |
| 85014 | <1% | 1,243 | $1K | |
| 85018 | <1% | 1,243 | $1K | |
| 82040 | <1% | 37,274 | $1K | |
| 86316 | <1% | 84 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 80 | $1K |
| 83002 | <1% | 67 | $990.08 | |
| 81025 | <1% | 16,194 | $975.36 | |
| 72050 | <1% | 13 | $956.24 | |
| 82670 | <1% | 43 | $933.80 | |
| 86706 | <1% | 119 | $933.66 | |
| 84075 | <1% | 37,236 | $922.15 | |
| 87536 | <1% | 13 | $893.86 | |
| 93880 | <1% | 13 | $865.32 | |
| 81002 | <1% | 19,899 | $822.42 | |
| 87328 | <1% | 99 | $778.60 | |
| 87329 | <1% | 99 | $778.60 | |
| 88112 | <1% | 65 | $777.88 | |
| 84481 | <1% | 56 | $725.16 | |
| 71101 | <1% | 305 | $723.49 | |
| 72040 | <1% | 66 | $677.32 | |
| 84145 | <1% | 1,897 | $648.08 | |
| 97163 | <1% | 12 | $641.34 | |
| 86003 | <1% | 12 | $632.46 | |
| 87430 | <1% | 123 | $584.92 | |
| 80178 | <1% | 178 | $523.73 | |
| 96376 | <1% | 6,016 | $523.63 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,107 | $516.81 |
| 84207 | <1% | 27 | $515.90 | |
| 83605 | <1% | 4,869 | $515.82 | |
| 82553 | <1% | 1,597 | $510.30 | |
| 82270 | <1% | 256 | $508.64 | |
| 83525 | <1% | 55 | $501.86 | |
| 84460 | <1% | 39,344 | $479.42 | |
| 83014 | <1% | 77 | $458.11 | |
| 86800 | <1% | 39 | $429.66 | |
| 82785 | <1% | 43 | $427.40 | |
| 97124 | <1% | 107 | $401.19 | |
| 86200 | <1% | 40 | $395.52 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 13 | $395.01 |
| 86747 | <1% | 540 | $373.36 | |
| 84436 | <1% | 136 | $355.91 | |
| 76870 | <1% | 26 | $348.63 | |
| 86765 | <1% | 34 | $337.51 | |
| 12011 | <1% | 68 | $325.50 | |
| 12001 | <1% | 688 | $299.03 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,883 | $284.65 |
| 82533 | <1% | 24 | $280.26 | |
| 86308 | <1% | 113 | $266.76 | |
| 97032 | <1% | 61 | $254.96 | |
| 84425 | <1% | 12 | $243.24 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,920 | $241.02 |
| 84155 | <1% | 36,930 | $239.66 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,751 | $227.46 |
| 73090 | <1% | 51 | $227.04 | |
| 90714 | <1% | 1,674 | $224.10 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,395 | $215.01 |
| 87420 | <1% | 209 | $206.10 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,337 | $184.90 |
| 86735 | <1% | 16 | $161.98 | |
| 73590 | <1% | 123 | $160.47 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,814 | $125.48 |
| 83021 | <1% | 26 | $120.68 | |
| 94761 | <1% | 4,215 | $113.48 | |
| 88304 | <1% | 784 | $111.05 | |
| 83921 | <1% | 13 | $110.04 | |
| 96367 | <1% | 15 | $104.84 | |
| 73560 | <1% | 21 | $98.72 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 216 | $81.42 |
| 86901 | <1% | 5,978 | $80.80 | |
| 85049 | <1% | 173 | $74.80 | |
| 82948 | <1% | 4,498 | $69.76 | |
| 88313 | <1% | 6,290 | $64.65 | |
| 84132 | <1% | 36 | $64.09 | |
| 94760 | <1% | 2,851 | $63.25 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,863 | $52.35 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,256 | $47.10 |
| 87207 | <1% | 59 | $43.23 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,168 | $41.78 |
| 36416 | <1% | 5,319 | $36.75 | |
| 86850 | <1% | 2,033 | $34.40 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 931 | $25.23 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,420 | $15.76 |
| 87210 | <1% | 499 | $13.83 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,043 | $11.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,716 | $9.17 |
| 81015 | <1% | 43 | $8.27 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,344 | $7.96 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,213 | $2.69 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 528 | $2.53 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $2.16 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,749 | $2.15 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 435 | $2.08 |
| A9150 | Non-prescription drugs | <1% | 2,324 | $1.97 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,073 | $1.74 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,043 | $1.48 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,353 | $0.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,747 | $0.73 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,936 | $0.58 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 147 | $0.50 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,407 | $0.46 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 772 | $0.09 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 3,084 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 913 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 86 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 102 | $0.00 |
| 94729 | 0% | 29 | $0.00 | |
| 29125 | 0% | 102 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 458 | $0.00 |
| 97598 | 0% | 2,126 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 59 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 229 | $0.00 |
| 82075 | 0% | 323 | $0.00 | |
| 93356 | 0% | 224 | $0.00 | |
| 93041 | 0% | 246 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 135 | $0.00 |
| 99442 | 0% | 227 | $0.00 | |
| 82800 | 0% | 15 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 223 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 73 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 26 | $0.00 |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 26 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 95 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 85 | $0.00 |
| 82009 | 0% | 14 | $0.00 | |
| 94727 | 0% | 29 | $0.00 | |
| 88312 | 0% | 16 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,994 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 947 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 1,637 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 818 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,789 | $0.00 |
| 97802 | 0% | 591 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 3,402 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,450 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 13,516 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,982 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 856 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,847 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,573 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 154 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 202 | $0.00 |
| 96368 | 0% | 119 | $0.00 | |
| 88307 | 0% | 66 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 132 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 23 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 234 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 138 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 140 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 160 | $0.00 |
| 12002 | 0% | 88 | $0.00 | |
| 88341 | 0% | 14 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 52 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 148 | $0.00 |
| 11045 | 0% | 168 | $0.00 | |
| 99070 | 0% | 46 | $0.00 | |
| 77001 | 0% | 20 | $0.00 | |
| 74019 | 0% | 13 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| 86920 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Prospect Waterbury, INC. | Waterbury, CT | $84.62M |
| Prospect Chartercare RWMC, LLC | Providence, RI | $57.10M |
| Prospect CCMC, LLC | Chester, PA | $40.89M |
| Prospect CT Medical Foundation, INC. | Manchester, CT | $34.07M |
| Prospect Rockville Hospital, INC. | Vernon, CT | $30.06M |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $10.94M |
| Prospect DCMH, LLC | Drexel Hill, PA | $10.37M |
| Prospect CCMC, LLC | Chester, PA | $5.46M |
| Alta Los Angeles Hospitals, INC. | Los Angeles, CA | $5.42M |
| Prospect CCMC, LLC | Chester, PA | $5.03M |
| Prospect CCMC, LLC | Chester, PA | $3.71M |
| Prospect Chartercare Physicians, LLC | Cranston, RI | $2.31M |
| Prospect Echn Home Health, INC. | Vernon, CT | $1.75M |
| Prospect Waterbury Home Health, INC. | Watertown, CT | $1.30M |
| Prospect Health Access Network, INC. | Chester, PA | $1.22M |
| Alta Newport Hospital, LLC | Tustin, CA | $1.16M |
| Prospect Health Access Network, INC. | Crum Lynne, PA | $924K |
| Prospect Health Access Network, INC. | Chester, PA | $872K |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $858K |
| Prospect Health Access Network, INC. | Drexel Hill, PA | $815K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.